Topic
13 stories from Planck Standard. Latest: July 15, 2026.
Phase 3 results showed young children with sickle cell disease or beta thalassemia became free of pain crises or transfusions after a single treatment that rewrites their own blood cells.
In animal models, a glycine-based tripeptide called DT-109 healed the intestinal barrier and rolled back MASH — a dangerous form of fatty liver disease that affects roughly 7% of people worldwide.
UCLA researchers report that the popular muscle-building compound energizes dendritic cells — the immune system's scouts — potentially making cancer immunotherapy work for far more patients.
A new study finds that measuring apoB — a protein tag on every harmful cholesterol particle — guides treatment better than the standard LDL test, and does it cost-effectively.
University of Washington scientists found that fibrolamellar carcinoma hides from immunotherapy by sequestering T cells in fibrous tissue — and that the FDA-approved drug AMD3100 lets them back in to kill the tumor.
Texas A&M researchers used a two-step growth-factor treatment to coax adult mice to rebuild bone, joints, ligaments and tendons after amputation — evidence that mammals may retain a dormant capacity to regenerate.
A sweeping University of Sydney analysis of dozens of conditions concludes that widely prescribed opioids deliver only small, short-lived relief, and sometimes none at all, while carrying real risks.
University of Vermont researchers discovered that H3N2 relies on a protein H1N1 doesn't need, overturning the idea that all influenza strains enter cells the same way.
Finerenone slowed kidney decline and cut the risk of heart failure and death across a far wider group of patients than it is prescribed for today — results published simultaneously in The Lancet, NEJM and JAMA.
Scientists behind Casgevy — the world's first CRISPR-based medicine — and Luxturna, the first gene replacement therapy to restore sight in children, were honored at the April 18 ceremony.
A landmark trial published in Nature Medicine reports that one injection of a corrective gene into the inner ear transformed profound deafness into functional hearing in every participant — including a seven-year-old girl now having everyday conversations.
UC Berkeley researchers discover that an ancient archaeon reads the universal stop codon ambiguously, sometimes inserting an amino acid instead of halting protein synthesis — with implications for treating 10% of all inherited diseases.
When a PhD student forgot to add a catalyst to his reaction, it worked better without it — leading to an 'anti-Friedel-Crafts' reaction published in Nature Synthesis that lets chemists fine-tune drug molecules at any stage of development using nothing more than an LED lamp.